Merck & Co., Inc. (TSX:MRK)
32.75
+0.13 (0.40%)
Nov 13, 2026, 4:00 PM EST
Merck & Co. Employees
As of December 31, 2025, Merck & Co. had 75,000 total employees, including 73,000 full-time and 2,000 part-time employees. The number of employees did not change compared to the previous year.
Employees
75,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
1.29M CAD
Profits / Employee
47.06K CAD
Market Cap
519.14B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 75,000 | 0 | - | 73,000 | 2,000 |
| Dec 31, 2024 | 75,000 | 3,000 | 4.17% | 73,000 | 2,000 |
| Dec 31, 2023 | 72,000 | 3,000 | 4.35% | 70,000 | 2,000 |
| Dec 31, 2022 | 69,000 | 1,000 | 1.47% | 67,000 | 2,000 |
| Dec 31, 2021 | 68,000 | -6,000 | -8.11% | 67,000 | 1,000 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Extendicare | 23,500 |
| Sienna Senior Living | 15,000 |
| Apotex Health | 6,000 |
| Curaleaf Holdings | 5,554 |
| Green Thumb Industries | 4,900 |
| WELL Health Technologies | 1,507 |
| Knight Therapeutics | 830 |
| Vireo Growth | 612 |
Merck & Co. News
- 3 days ago - Merck announces European CHMP recommends approval of Enflonsia - TheFly
- 3 days ago - Merck announces European CHMP recommends approval of Enflonsia - TheFly
- 3 days ago - Merck reports European CHMP recommends approval of Welireg - TheFly
- 3 days ago - Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season - Business Wire
- 3 days ago - Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy - Business Wire
- 4 days ago - The world's most sophisticated drug companies are putting billions into vaccines — despite the political environment - Market Watch
- 4 days ago - Surrozen price target raised to $80 from $42 at Guggenheim - TheFly
- 4 days ago - Merck to Participate in the Jefferies Global Healthcare Conference in London - Business Wire